Neurocrine Biosciences Inc (Neurocrine) focuses on the discovery, development, and commercialization of drugs for the treatment of neurological, psychiatric, endocrine, and immunological disorders. The company offers a range of modalities including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. The company’s customers include select specialty pharmacy providers, wholesale distributors, and specialty distributors. It sells INGREZZA exclusively in the US through a limited specialty network.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Neurocrine's R&D arm focuses on all areas across neurology, psychiatry, endocrinology, and immunology. The company's R&D pipeline is fueled by core expertise in receptor biology developed over three decades, leveraging validated biological pathways and novel modalities to advance potential first-in-class or best-in-class treatment candidates for patients with serious and under-addressed conditions. The company aims to maintain a balanced portfolio by stage of development and across therapeutic areas, targeting prevalent central nervous system disorders and rare/orphan diseases. The company has a strategy to launch approximately one new medicine every two years, driven by internal investments in discovery and strategic business development. The R&D units of Neurocrine include the Research and Discovery unit and the Clinical Development unit. The Research and Discovery unit focuses on discovery research and preclinical development activities, including lead optimization, nonclinical studies, preclinical manufacturing, and toxicology. The Clinical Development unit manages the progression of product candidates through various phases of clinical trials, ensuring a steady cadence of innovative medicines. As of December 2024, the company had a portfolio of 22 issued US patents for Ingrezza, set to expire between 2027 and 2040. CRENESSITY is covered by 4 issued US patents which are set to expire between 2035 and 2041. In FY2025, the company spent US$1,015.7 million on its R&D activities, which as a percentage of revenue stood at 35.5%, and grew 38.9% YoY.